Attic®

Atorvastatin Calcium Tablets

Composition

Attic®-10

Each film-coated tablet contains:
Atorvastatin calcium equivalent to Atorvastatin IP 10 mg

Indications

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin can be started simultaneously with diet.

Prevention of Cardiovascular Disease

In adult patients without clinically evident CHD, but with multiple risk factors for CHD such as age, smoking, hypertension, low HDL-C, or a family history of early CHD, Attic® is indicated to:

Reduce the risk of myocardial infarction
Reduce the risk of stroke
Reduce the risk for revascularization procedures and angina

In patients with type 2 diabetes, and without clinically evident CHD, but with multiple risk factors for CHD such as retinopathy, albuminuria, smoking, or hypertension, Attic® is indicated to:

Reduce the risk of myocardial infarction

Reduce the risk of stroke

In patients with clinically evident CHD, Attic® is indicated to:

Reduce the risk of non-fatal myocardial infarction

Reduce the risk of fatal and non-fatal stroke

Reduce the risk for revascularization procedures

Reduce the risk of hospitalization for CHF

Reduce the risk of angina

Hypercholesterolemia

Attic® is indicated:

As an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apo B and triglyceride levels and to increase HDL-C in patients with primary hypercholesterolaemia (heterozygous familial and nonfamilial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb).

As adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV).

For the treatment of patients with primary dysbetalipoproteinaemia (Fredrickson Type III) who do not respond adequately to diet.

To reduce total cholesterol and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.

As an adjunct to diet to reduce total cholesterol, LDL-C and apo B levels in boys and menarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolaemia, if after an adequate trial of diet therapy, the following findings are present:

LDL-C remains ≥ 190 mg/dl or

LDL-C remains ≥ 160 mg/dl and

There is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease (CVD) risk factors are present in the pediatric patient

Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate.

PRESENTATION & PACKAGING

Attic® -     White, round, bi-convex, film-coated tablet.
                Alu - Alu blister pack of 10 s

For Precautions and Drug Interactions please consult full Product Information or write to us.

® - Registered Trade Mark of Quality Innovations and Pharmaceuticals (India) Pvt Ltd.

Disclaimer

The drug information is intended for the use of a registered medical practitioner only. If you are not a medical professional, you should note that this document does not provide professional medical advice and is not intended to replace personal consultation with a qualified physician and should not be relied upon solely for final treatment decisions. Company reserves right to change Product presentation, display, capsule colors, tablet size,forms etc without prior notice.